IL6 and COVID-19: Focusing on the potential impact of pharmacological treatment for COVID-19 on the occurrence of thrombosis in the present cohort, patients who were administered corticosteroid therapy and anti-IL6 or anti-IL6R monoclonal antibody were significantly more often diagnosed with thromboembolism.